News & Events
MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing…
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China
Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in…
George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting
Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in…
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International…
Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy
Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research…
MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients
Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded…